The H19 locus acts in vivo as a tumor suppressor

Proceedings of the National Academy of Sciences of the United States of America

Volumn 105, Issue 34, 2008, Pages 12417-12422

  Yoshimizu, Tomomi ^a   Miroglio, Audrey ^a   Ripoche, Marie Anne ^a   Gabory, Anne ^a   Vernucci, Maria ^b   Riccio, Andrea ^b   Colnot, Sabine ^a   Godard, Cécile ^a   Terris, Benoit ^a   Jammes, Hélène ^a   Dandolo, Luisa ^a  

^a INSTITUT COCHIN   (France)

^b SECOND UNIVERSITY OF NAPLES   (Italy)

Author keywords

Genomic imprinting; Igf2; Murine models

Indexed keywords

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANCER SIZE; CARCINOGENESIS; COLORECTAL CANCER; CONTROLLED STUDY; EMBRYO; FEMALE; GENE LOCUS; LIVER CELL CARCINOMA; MALE; NONHUMAN; POLYP; PRIORITY JOURNAL; TERATOCARCINOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; COLORECTAL NEOPLASMS; DISEASE MODELS, ANIMAL; GENES, TUMOR SUPPRESSOR; INSULIN-LIKE GROWTH FACTOR II; MICE; MICE, MUTANT STRAINS; MULTIGENE FAMILY; RNA, UNTRANSLATED; TERATOMA;

MURINAE; MUS;

EID: 50449095151     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.0801540105     Document Type: Article

References (31)

1. Bartolomei MS, Zemel S, Tilghman SM (1991) Parental imprinting of the mouse H19 gene. Nature 351:153-155.
2. Gabory A, Ripoche MA, Yoshimizu T, Dandolo L (2006) The H19 gene: Regulation and function of a non-coding RNA. Cytogenet Genome Res 113:188-193.
3. DeChiara TM, Robertson EJ, Efstratiadis A (1991) Parental imprinting of the mouse insulin-like growth factor II gene. Cell 64:849-859.
4. Thorvaldsen JL, Duran KL, Bartolomei MS (1998) Deletion of the H19 differentially methylated domain results in loss of imprinted expression of H19 and Igf2. Genes Dev 12:3693-3702.
5. Weksberg R, Smith AC, Squire J, Sadowski P (2003) Beckwith-Wiedemann syndrome demonstrates a role for epigenetic control of normal development. Hum Mol Genet 12:R61-R68.
6. Cooper WN, et al. (2005) Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet 13:1025-1032.
7. Moulton T, et al. (1994) Epigenetic lesions at the H19 locus in Wilms' tumor patients. Nat Genet 7:440-447.
8. Feinberg AP (1999) Imprinting of a genomic domain of 11p15 and loss of imprinting in cancer: An introduction. Cancer Res 59:1743s-1746s.
9. Rump P, Zeegers MP, van Essen AJ (2005) Tumor risk in Beckwith-Wiedemann syndrome: A review and meta-analysis. Am J Med Genet A 136:95-104.
10. Hao Y, Crenshaw T, Moulton T, Newcomb E, Tycko B (1993) Tumor-suppressor activity of H19 RNA. Nature 365:764-767.
11. Lustig-Yariv O, et al. (1997) The expression of the imprinted genes H19 and IGF-2 in choriocarcinoma cell lines. Is H19 a tumor suppressor gene? Oncogene 15:169-177.
12. Verkerk A, et al. (1997) Unique expression patterns of H19 in human testicular cancers of different etiology. Oncogene 14:95-107.
13. Dao D, et al. (1999) Multipoint analysis of human chromosome 11p15/mouse distal chromosome 7: Inclusion of H19/IGF2 in the minimal WT2 region, gene specificity of H19 silencing in Wilms' tumorigenesis and methylation hyper-dependence of H19 imprinting. Hum Mol Genet 8:1337-1352.
14. Frevel MA, Sowerby SJ, Petersen GB, Reeve AE (1999) Methylation sequencing analysis refines the region of H19 epimutation in Wilms tumor. J Biol Chem 274:29331-29340.
15. Matouk IJ, et al. (2007) The H19 non-coding RNA is essential for human tumor growth. PLoS ONE 2:e845.
16. Ripoche MA, Kress C, Poirier F, Dandolo L (1997) Deletion of the H19 transcription unit reveals the existence of a putative imprinting control element. Genes Dev 11:1596-1604.
17. Leighton PA, Saam JR, Ingram RS, Stewart CL, Tilghman SM (1995) An enhancer deletion affects both H19 and Igf2 expression. Genes Dev 9:2079-2089.
18. Damjanov I, Solter D, Skreb N (1971) Teratocarcinogenesis as related to the age of embryos grafted under the kidney capsule. Wilhelm Roux' Archiv 107:288-290.
19. Colnot S, et al. (2004) Colorectal cancers in a new murine model of familial adenomatous polyposis: Influence of genetic and environmental modifiers. Lab Invest 84:1619-1630.
20. Vernucci M, et al. (2000) The H19 endodermal enhancer is required for Igf2 activation and tumor formation in experimental liver carcinogenesis. Oncogene 19:6376-6385.
21. Vernucci M, et al. (2004) Developmentally regulated functions of the H19 differentially methylated domain. Hum Mol Genet 13:353-361.
22. Hassan AB, Howell JA (2000) Insulin-like growth factor II supply modifies growth of intestinal adenoma in Apc(Min/+) mice. Cancer Res 60:1070-1076.
23. Leighton PA, Ingram RS, Eggenschwiler J, Efstratiadis A, Tilghman SM (1995) Disruption of imprinting caused by deletion of the H19 gene region in mice. Nature 375:34-39.
24. Sakatani T, et al. (2005) Loss of imprinting of Igf2 alters intestinal maturation and tumorigenesis in mice. Science 307:1976-1978.
25. Ruther U, Woodroofe C, Fattori E, Ciliberto G (1993) Inducible formation of liver tumors in transgenic mice. Oncogene 8:87-93.
26. Casola S, et al. (1995) Loss of heterozygosity of imprinted genes in SV40 t/T antigen-induced hepatocellular carcinomas. Oncogene 11:711-721.
27. Stevens LC (1970) The development of transplantable teratocarcinomas from intratesticular grafts of pre- and postimplantation mouse embryos. Dev Biol 21:364-382.
28. Mann JR, Gadi I, Harbison ML, Abbondanzo SJ, Stewart CL (1990) Androgenetic mouse embryonic stem cells are pluripotent and cause skeletal defects in chimeras: Implications for genetic imprinting. Cell 62:251-260.
29. Mineno J, et al. (2006) The expression profile of microRNAs in mouse embryos. Nucleic Acids Res 34:1765-1771.
30. Cai X, Cullen BR (2007) The imprinted H19 noncoding RNA is a primary microRNA precursor. RNA 13:313-316.
31. DeChiara TM, Efstratiadis A, Robertson EJ (1990) A growth deficiency phenotype in heterozygous mice carrying an insulin-like growth factor II gene disrupted by gene targeting. Nature 345:78-80.